SCHEMBL9933672

SCHEMBL9933672

CC(C)(C)OC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4occc34)CC2)CC1

nearest known ligand 0.78

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 20/20 0.78
HTR2A P28223 20/20 0.78
DRD3 P35462 20/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9933617 1.00 DRD2 (0.78) DRD2HTR2ADRD3
SCHEMBL13584122 0.88 DRD2 (0.78) DRD2HTR2ADRD3
SCHEMBL13584120 0.88 DRD2 (0.78) DRD2HTR2ADRD3
SCHEMBL9933709 0.88 DRD2 (1.00) DRD2HTR2ADRD3
SCHEMBL9933708 0.88 DRD2 (1.00) DRD2HTR2ADRD3
SCHEMBL9933350 0.86 DRD2 (1.00) DRD2HTR2ADRD3
SCHEMBL9933353 0.86 DRD2 (1.00) DRD2HTR2ADRD3
SCHEMBL9934155 0.86 DRD2 (1.00) DRD2HTR2ADRD3
SCHEMBL9934158 0.86 DRD2 (1.00) DRD2HTR2ADRD3
SCHEMBL9933387 0.84 DRD2 (1.00) DRD2HTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3268375-B1 PHOTOCHROMIC THIENOCHROMENE COMPOUNDS TRANSITIONS OPTICAL INC (US) 2022-06-15 EP disclosed
EP-3071576-B9 PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS TRANSITIONS OPTICAL INC (US) 2021-12-22 EP disclosed
US-20210317129-A1 Indolenaphthopyrans TRANSITIONS OPTICAL, LTD. (IE) 2021-10-14 US disclosed
EP-3071576-B1 PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS TRANSITIONS OPTICAL INC (US) 2021-08-18 EP disclosed
CN-113150007-A Photochromic indeno-fused ring pyran compounds 光学转变公司 2021-07-23 CN disclosed
CN-107406459-B Photochromic thienobenzopyran compounds 光学转变公司 2021-06-08 CN disclosed
CN-109096088-B Process for preparing fused ring indeno compounds 光学转变公司 2021-04-30 CN disclosed
CN-105829283-B Fused ring indeno compounds for preparing photochromic compounds 光学转变公司 2020-10-27 CN disclosed
CN-105849089-B Process for preparing fused ring indeno compounds 光学转变公司 2020-10-09 CN disclosed
EP-3071550-B1 METHOD OF PREPARING FUSED RING INDENO COMPOUNDS TRANSITIONS OPTICAL INC (US) 2019-03-13 EP disclosed
WO-2015077147-A1 METHOD OF PREPARING FUSED RING INDENO COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2015-05-28 WO disclosed
WO-2015077141-A1 FUSED RING INDENO COMPOUNDS FOR PREPARATION OF PHOTOCHROMIC COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2015-05-28 WO disclosed
WO-2015077264-A1 PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2015-05-28 WO disclosed
US-20150141661-A1 Photochromic Indeno-Fused Ring Pyran Compounds TRANSITIONS OPTICAL, INC. (US) 2015-05-21 US disclosed
US-20150141662-A1 Method Of Preparing Fused Ring Indeno Compounds TRANSITIONS OPTICAL, INC. (US) 2015-05-21 US disclosed
US-20150141663-A1 Fused Ring Indeno Compounds For Preparation Of Photochromic Compounds TRANSITIONS OPTICAL, INC. (US) 2015-05-21 US disclosed
EP-2651914-B1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL INC (US) 2015-05-13 EP disclosed
US-9029565-B1 Fused ring indeno compounds for preparation of photochromic compounds TRANSITIONS OPTICAL, INC. (US) 2015-05-12 US disclosed
US-8920928-B2 Photochromic compounds and compositions TRANSITIONS OPTICAL, INC. (US) 2014-12-30 US disclosed
US-20120156508-A1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL, INC. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141662-A1 Method Of Preparing Fused Ring Indeno Compounds INHA, INTS9, CA9 DRD2 3394/4885HTR2A 3539/4885DRD3 2148/4885
US-20150141663-A1 Fused Ring Indeno Compounds For Preparation Of Photochromic Compounds IPO5, INCENP, NQO1 DRD2 2024/4885HTR2A 1223/4885DRD3 1264/4885
US-20210317129-A1 Indolenaphthopyrans AHR, TDO2, TPH2 DRD2 455/4885HTR2A 76/4885DRD3 159/4885
US-20150141661-A1 Photochromic Indeno-Fused Ring Pyran Compounds INF2, INCENP, RB1 DRD2 557/4885HTR2A 535/4885DRD3 68/4885
US-20120156508-A1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS CRY2, CRY1, IPO4 DRD2 2059/4885HTR2A 478/4885DRD3 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.